Previously, it has been shown that CC-115, an inhibitor of mTOR and DNA-PK, chemically dissimilar from rapamycin, can effectively kill CLL cells resistant to ibrutinib both in preclinical models and in the clinical setting [31]. The gene discussed is MTOR; the disease is B-cell chronic lymphocytic leukemia.